Industry News

TMCNet:  LifeWatch Services Unveils LifeStar ACT III Platinum

[October 03, 2008]

LifeWatch Services Unveils LifeStar ACT III Platinum

(Wireless News Via Acquire Media NewsEdge)
Card Guard, the parent company of LifeWatch, announced that LifeWatch
has launched its next-generation LifeStar ACT III Platinum (ACT III)
monitor in the United States.

The advanced monitoring device, cleared by the FDA in June, provides
enhanced heart arrhythmia detection through its 3-channel ECG
functionality and ST deviation analysis that can measure ischemic
changes. The ACT III monitor automatically detects and sends heart
rhythm abnormalities to a 24/7 LifeWatch monitoring call center. This
call center is staffed by certified cardiac technicians, who interpret
the data and initiate physician notification based on pre-determined
criteria. The ACT III monitor, which requires only minimal patient
intervention, improves patient compliance and increases diagnostic

The ACT III monitor offers broader functionality with its
high-performance multi-channel Ambulatory Cardiac Telemetry in one
simple-to-use system. With up to 21-days of real-time ECG monitoring
and the provision of ST deviation analysis, the ACT III provides more
sensitive and specific data for initial or early detection of
arrhythmia in patients that have limited or atypical symptoms. The
device has 6 hours of memory in the sensor and a flash memory of up to
21 days of data on the ACT Cell phone monitor. This ensures that no
valuable data is lost if a patient is disconnected from the cellular
phone. The algorithm and advanced wireless and web-based technologies
of ACT III enhances data collection, analysis, transmission and
reporting, and can be utilized in standard and alternative patient
monitoring programs, such as Specialized Atrial Fibrillation (AF)
Patient Care and Congestive Heart Failure (CHF) programs.

"In my opinion, real-time outpatient cardiac monitoring using this new
and unique 3-channel configuration will extend physicians management of
patient conditions which have been traditionally monitored in an
inpatient setting. Disease state management requires more accurate
diagnostic tools such as the ACT III to allow for early detection of a
worsening condition in patients that are minimally symptomatic," said
Dr. Harry A. Kopelman, Director of the Cardiac Electrophysiology
Laboratory at the Fuqua Heart Center & the Piedmont Heart Institute.

LifeWatch through its operating subsidiaries Lifewatch Services and
LifeWatch Technologies, is an independent provider of ambulatory
cardiac monitoring services and a manufacturer and distributor of
ambulatory cardiac and vital signs monitoring devices in the United

((Comments on this story may be sent to

((Distributed on behalf of 10Meters via M2 Communications Ltd -
((10Meters -

Copyright ? 2008 Wireless News

[ Back To Contact Center Solutions's Homepage ]